Uma Sinha - BridgeBio Pharma Chief Officer
| BBIO Stock | USD 27.49 1.05 3.97% |
Insider
Uma Sinha is Chief Officer of BridgeBio Pharma
| Age | 66 |
| Address | 3160 Porter Drive, Palo Alto, CA, United States, 94304 |
| Phone | 650 391 9740 |
| Web | https://bridgebio.com |
BridgeBio Pharma Management Efficiency
The company has return on total asset (ROA) of (0.4888) % which means that it has lost $0.4888 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (17.8967) %, meaning that it created substantial loss on money invested by shareholders. BridgeBio Pharma's management efficiency ratios could be used to measure how well BridgeBio Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of November 2024, Return On Equity is likely to grow to 0.50, while Return On Tangible Assets are likely to drop (1.30). At this time, BridgeBio Pharma's Total Assets are very stable compared to the past year. As of the 28th of November 2024, Non Current Assets Total is likely to grow to about 74.3 M, though Net Tangible Assets are likely to grow to (1.1 B).Similar Executives
| Showing other executives | INSIDER Age | ||
| Keith MD | X4 Pharmaceuticals | 53 | |
| MD MBA | Amylyx Pharmaceuticals | 63 | |
| Katherine Tuminello | Krystal Biotech | N/A | |
| MS MBA | Krystal Biotech | 59 | |
| Mary DiBiase | X4 Pharmaceuticals | 63 | |
| Shauna Horvath | Amylyx Pharmaceuticals | N/A | |
| MS MBA | Inozyme Pharma | 47 | |
| Dr MBA | Blueprint Medicines Corp | 54 | |
| Weidong Zhong | Terns Pharmaceuticals | 58 | |
| Kerry MD | Terns Pharmaceuticals | N/A | |
| James MBA | Amylyx Pharmaceuticals | 57 | |
| MBA JD | Apellis Pharmaceuticals | 51 | |
| MBA MBA | Inozyme Pharma | 65 | |
| Demetrios MD | Inozyme Pharma | N/A | |
| Richard MD | X4 Pharmaceuticals | 61 | |
| Julie Bockenstette | Acumen Pharmaceuticals | N/A | |
| Alex Kane | PTC Therapeutics | N/A | |
| Siew MS | Acumen Pharmaceuticals | N/A | |
| Federico MD | Apellis Pharmaceuticals | 50 | |
| Henric Bjarke | Inozyme Pharma | 57 | |
| Joshua Cohen | Amylyx Pharmaceuticals | 32 | |
Management Performance
| Return On Equity | -17.9 | ||||
| Return On Asset | -0.49 |
BridgeBio Pharma Leadership Team
Elected by the shareholders, the BridgeBio Pharma's board of directors comprises two types of representatives: BridgeBio Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BridgeBio. The board's role is to monitor BridgeBio Pharma's management team and ensure that shareholders' interests are well served. BridgeBio Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BridgeBio Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Neil Kumar, President, CoFounder | ||
| MBA CPC, Chief Officer | ||
| Richard Scheller, Chairman Development | ||
| Dr CFA, CFO Secretary | ||
| Eli Wallace, Chief Oncology | ||
| Frank McCormick, CoFounder Oncology | ||
| Thomas Trimarchi, Chief Officer | ||
| Uma Sinha, Chief Officer | ||
| Charles MD, Chairman CoFounder | ||
| Grace Rauh, Vice Communications | ||
| JD MD, Chief Therapy |
BridgeBio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BridgeBio Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -17.9 | ||||
| Return On Asset | -0.49 | ||||
| Profit Margin | (2.02) % | ||||
| Operating Margin | (68.50) % | ||||
| Current Valuation | 6.46 B | ||||
| Shares Outstanding | 188.99 M | ||||
| Shares Owned By Insiders | 5.39 % | ||||
| Shares Owned By Institutions | 94.45 % | ||||
| Number Of Shares Shorted | 17.2 M | ||||
| Price To Earning | (13.72) X |
Pair Trading with BridgeBio Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BridgeBio Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BridgeBio Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against BridgeBio Stock
| 0.5 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.37 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.34 | OPT | Opthea | PairCorr |
The ability to find closely correlated positions to BridgeBio Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BridgeBio Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BridgeBio Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BridgeBio Pharma to buy it.
The correlation of BridgeBio Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BridgeBio Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BridgeBio Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BridgeBio Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.42) | Revenue Per Share 1.194 | Quarterly Revenue Growth (0.33) | Return On Assets (0.49) | Return On Equity (17.90) |
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.